Anta Gkelou is currently Principal at Sofinnova Partners, having joined the company in 2017.
Prior to joining Sofinnova Partners, Anta was an Immunology Scientist in the Life Sciences Division of Danone Nutricia Research.
Anta obtained a PhD in Clinical Medical Research from the National Heart and Lung Institute at Imperial College, London, in collaboration with Pfizer, where she worked on elucidating the mechanisms by which oxidative stress drives corticosteroid insensitivity in COPD. She conducted her post-doctoral training at the French National Institute of Health and Medical Research (INSERM) on immune regulation of the cardiac contractile machinery and function post myocardial infarction.
Anta holds a first-class BSc in Molecular Biology from University of Liverpool, UK.